For those interested, Acadia have just presented at the 39th J P Morgan healthcare conference. They confirmed that the Phase 3 trial for Retts remains on schedule for H2 2021. I would suggest that means the last patient to enroll is very close. This should be a market sensitive announcement as it is a significant milestone. I can provide countless other Boitechs who have announced same and been deemed market sensitive. IMU announced on 7th January.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
-0.280(1.39%) |
Mkt cap ! $2.509B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.83 | $19.84 | $10.48M | 512.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 260 | $19.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.86 | 237 | 13 |
View Market Depth
| Last trade - 14.49pm 19/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |